Search results for "Cutaneous"

showing 10 items of 1022 documents

Controlled iontophoretic release of glucocorticoids through epithelial cell monolayers

1998

In the present study the iontophoretic transdermal delivery of three different glucocorticoids through a confluent monolayer of MDCK cells, mimicking biological barriers, was studied. For this experiment an in vitro model with platinum electrodes for iontophoresis and MDCK cells was developed. With this model investigations concerning the biocompatibility of the cells depending on different current densities and the iontophoretic permeation of the three glucocorticoids through the cell monolayer were carried out. The permeation behavior of this living biological barrier should be very similar to the non-living barrier, human stratum corneum. Different current densities (12.74-38.22 microA/c…

BiocompatibilityIontophoresisChemistryPharmaceutical ScienceEpithelial CellsIontophoresisPharmacologyPermeationAdministration CutaneousPermeabilityCell LineDogsmedicine.anatomical_structureCell culturePermeability (electromagnetism)MonolayerStratum corneummedicineBiophysicsAnimalsHumansGlucocorticoidsTransdermalJournal of Controlled Release
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters

2016

Backgrounds and aims: Low concentrations of plasma HDL-C are associated with the development of atherosclerotic cardiovascular diseases and type 2 diabetes. Here we aimed to explore the relationship between the in vivo fractional synthesis of triglycerides (fTG) in subcutaneous (s.q.) abdominal adipose tissue (AT), HDL-C concentrations and HDL particle size composition in non-diabetic humans. Methods: The fTG in s.q. abdominal AT was measured in 16 non-diabetic volunteers (7 women, 9 men; Age: 49 ± 20 years; BMI: 31 ± 5 kg/m; Fasting Plasma Glucose: 90 ± 10 mg/dl) after 2H2O labeling. HDL-C concentration and subclasses, large (L-HDL), intermediate (I-HDL) and small (S-HDL) were measured. Re…

Blood GlucoseMale0301 basic medicinemedicine.medical_specialtyAdipocyte; Atheroprotective; Gender-related; HDL-C metabolism; Mass spectrometry; Stable isotope tracer kinetics; Triglycerides; Cardiology and Cardiovascular MedicineAdipose tissueWhite adipose tissueType 2 diabetes030204 cardiovascular system & hematologyTriglycerideArticleAtheroprotective03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceIn vivoInternal medicineAdipocytemedicineHumansObesityTriglyceridesAgedHDL-C metabolismAdipocyteStable isotope tracer kineticMass spectrometrybusiness.industryLipogenesisCholesterol HDLnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseLipidsObesitySubcutaneous Fat AbdominalGender-related030104 developmental biologyEndocrinologychemistryLipogenesisFemalelipids (amino acids peptides and proteins)Insulin ResistanceCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)

1990

• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms. ( Arch Intern Med. 1990;150:2401-2402)

Blood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousHypoglycemiaOctreotideRefractoryInternal medicineInternal MedicinemedicineHumansInsulinOral glucose toleranceSevere disorderGlucose tolerance testReactive hypoglycemiaC-Peptidemedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseHypoglycemiaSomatostatin AnaloguePostprandialEndocrinologyFoodbusinessArchives of Internal Medicine
researchProduct

Revascularisation of a Giant Coronary Artery Aneurysm in Suspected Incomplete Kawasaki-Disease

2006

Kawasaki disease leads to typical vascular complications in up to 20 % of untreated cases. We describe a 47-year-old patient with coronary vessel disease, involving the right coronary artery with a huge aneurysmatic dilatation, suspicious for an incomplete form of Kawasaki disease. We found little information about the surgical treatment and postoperative course of this disease in adults. Typically, these infrequent patients present with acute myocardial infarction and require interdisciplinary decision-making.

Brain InfarctionPulmonary and Respiratory Medicinemedicine.medical_specialtyMyocardial InfarctionDiseaseMucocutaneous Lymph Node SyndromeCoronary AngiographyPostoperative ComplicationsAneurysmInternal medicinemedicine.arterymedicineHumanscardiovascular diseasesMyocardial infarctionCoronary Artery BypassSurgical treatmentCoronary artery aneurysmbusiness.industryCoronary ThrombosisCoronary AneurysmMiddle Agedmedicine.diseaseAortic DissectionIntracranial EmbolismRight coronary arteryCoronary vesselCardiologySurgeryKawasaki diseaseCardiology and Cardiovascular MedicinebusinessThe Thoracic and Cardiovascular Surgeon
researchProduct

Topical treatment with a two-component gel releasing nitric oxide cures C57BL/6 mice from cutaneous leishmaniasis caused by Leishmania major.

2016

C57BL/6medicine.medical_specialty030231 tropical medicineDrug Evaluation PreclinicalLeishmaniasis CutaneousTopical treatmentDermatologyPharmacologyAdministration CutaneousBiochemistryNitric oxide030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCutaneous leishmaniasismedicineAnimalsLeishmania majorNitric Oxide DonorsMolecular BiologyLeishmania majorbiologybusiness.industryLeishmaniasisbiology.organism_classificationmedicine.diseaseDermatologyMice Inbred C57BLchemistrybusinessGelsExperimental dermatology
researchProduct

Microcystic pseudoglandular plexiform cutaneous neurofibroma

2015

Glandular structures are well documented to appear in peripheral nerve sheath tumors. These epithelial elements are usually present in malignant peripheral nerve sheath tumors although a few cases of glandular benign peripheral nerve sheath tumors have also been described, most of them being schwannomas. A neurofibroma with glands is considered to be a rare type of divergent differentiation, but a neurofibroma containing gland-like or pseudoglandular structures have not, to our knowledge, been described. We report a 33-year-old patient with a well-demarcated dermal neoplasm, composed of neoplastic Schwann cells, perineurial-like cells and fibroblasts in a matrix with collagen fibers and myx…

CD31Pathologymedicine.medical_specialtyHistologybusiness.industryCutaneous neurofibromaDermal NeoplasmDermatologyAnatomyMatrix (biology)medicine.diseasePathology and Forensic MedicineCytokeratinMedicineNeurofibromaEpithelial Membrane AntigenbusinessImmunostainingJournal of Cutaneous Pathology
researchProduct

Cutaneous leishmaniasis: Distinct functions of dendritic cells and macrophages in the interaction of the host immune system with Leishmania major

2017

Leishmaniasis is transmitted by sand flies leading to parasite inoculation into skin. In the mammalian host, the parasite primarily resides in skin macrophages (MΦ) and dendritic cells (DC). MΦ are silently invaded by the parasite eliciting a stress response, whereas DC become activated, release IL-12, and prime antigen-specific T cells. Here we review the basics of the immune response against this human pathogen and elucidate the role and function DC and MΦ for establishment of protective immunity against leishmaniasis. We focus on cell type-specific differences in parasite uptake, phagocyte activation and processing of parasite antigens to facilitate an understanding how their respective …

CD4-Positive T-Lymphocytes0301 basic medicineMicrobiology (medical)Leishmaniasis CutaneousAntigens ProtozoanMicrobiology03 medical and health sciencesImmune systemPhagocytosisCutaneous leishmaniasisAntigenmedicineAnimalsHumansMacrophageLeishmania majorLeishmania majorSkinbiologyMacrophagesDendritic CellsGeneral MedicineDendritic cellmedicine.diseasebiology.organism_classificationLeishmania030104 developmental biologyInfectious DiseasesVacuolesImmunologyInterleukin 12International Journal of Medical Microbiology
researchProduct

Low zone tolerance induced by systemic application of allergens inhibits TC1-mediated skin inflammation

2005

Background The induction of tolerance may be a promising target of strategies aimed at preventing harmful allergic diseases. Low zone tolerance (LZT), induced by epicutaneous application of low doses of contact allergens, inhibits the development of T C 1-mediated contact hypersensitivity (CHS). Objective We evaluated the effect of systemic (oral, intravenous) administration of low amounts of haptens on specific immune reactions and tolerance induction. Methods By using the mouse model of LZT, we analyzed immune reactions in vivo (skin inflammation) and T-cell responses in vitro after oral, intravenous, or epicutaneous application of low amounts of the contact allergen 2,4,6-trinitro-1-chlo…

CD4-Positive T-LymphocytesAdoptive cell transferAllergymedicine.medical_treatmentImmunologyDose-Response Relationship ImmunologicAdministration OralInflammationPicryl ChlorideAdministration CutaneousDermatitis ContactT-Lymphocytes RegulatoryImmune toleranceMiceImmune systemImmune TolerancemedicineAnimalsImmunology and AllergyMice KnockoutChemistryCell DifferentiationImmunotherapyAllergensmedicine.diseaseMice Inbred C57BLTolerance inductionTrinitrobenzenesulfonic AcidOrgan SpecificityInjections IntravenousImmunologymedicine.symptomCD8T-Lymphocytes CytotoxicJournal of Allergy and Clinical Immunology
researchProduct